Cellionyx was founded on a singular mission: to engineer healing at the cellular level. After seeing the limitations of conventional therapies firsthand, Sanjay assembled a world-class team to build technology that works with the body's intelligence.
To revolutionize healing through first-in-class, non-invasive electroceutical and bioelectric medicine—transforming how the medical community approaches neurovascular recovery, tissue repair, pain management, and regenerative medicine by engineering solutions that work at the cellular level.
A world where every patient has access to advanced, non-invasive healing technologies that accelerate recovery, reduce pain, and restore function faster than ever thought possible.
Founder & CEO
Sanjay is a seasoned technology entrepreneur with 30+ years of global experience in innovation and venture development. He founded Equstech, where he developed the K2 device—a pioneering non-invasive bioelectric therapeutic tool for equine rehabilitation. His vision for Cellionyx stems from firsthand experience with bioelectric healing technology and a deep understanding of performance recovery needs across both human and veterinary applications.
Expertise: Bioelectric therapeutic technology, medical device development, venture leadership
Previous Ventures: Equstech (veterinary bioelectric devices), technology ventures in ERP/CRM solutions
Background: 30+ years global technology and innovation experience
Vision: Bringing proven bioelectric healing technology from veterinary success to human healthcare
Sanjay establishes Cellionyx with initial seed funding and begins developing core EDCMC technology.
Research and development focused on engineering our proprietary EDCMC waveform architecture and net-charge-balanced cellular signaling principles.
Advancement of multi-channel waveform synthesis and dry-contact conductive bio-interface materials for deep tissue field penetration.
Precision hardware and firmware development integrating real-time tissue impedance telemetry and automated polarity management.
Blinded clinical ultrasound and muscle biopsy validation demonstrating 2x–5x mitochondrial biogenesis (p<0.001) and deep spinal symmetry restoration.
Refining the Cytomotion™ clinical architecture and expanding multi-channel neurovascular and musculoskeletal protocols.
Development of the V9 (V-Series) modular conformal garment ecosystem and longitudinal hospital validation on GE LOGIQ e Spectral Doppler (+94.9% leg & +46.1% wrist arterial volume flow; +114.2% deep venous return) and 6-channel Artinis PortaMon MKIII NIRS (-10.1 µM deep fluid evacuation) across 23 clinical indications.
Combining hardware systems engineering, vascular ultrasonography, near-infrared optical spectroscopy, cellular biophysics, and FDA regulatory strategy.
Cellionyx is advancing the V9 (V-Series) non-invasive electroceutical platform through a disciplined, two-stage U.S. FDA regulatory pathway aligned with ISO 13485 quality management, IEC 60601-1 electrical safety, and ISO 10993 biocompatibility standards.
Targeting foundational clearance for increasing local blood circulation, preventing muscular disuse atrophy, neuromuscular re-education, and acute/chronic pain management—supported by 55 longitudinal hospital GE LOGIQ e Doppler captures (+94.9% lower-extremity and +46.1% upper-extremity arterial volume flow) and 346,853 continuous 10 Hz Artinis PortaMon MKIII NIRS optical readings.
Following foundational Class II clearance, expanding label indications into disease-specific regenerative claims—including Diabetic Peripheral Neuropathy (DPN), Chemotherapy-Induced Peripheral Neuropathy (CIPN), Refractory Diabetic Foot Ulcers (DFU), and Lymphedema—through multi-center IRB-approved randomized controlled clinical trials.
Request a clinical demo to see how Cytomotion™ can integrate into your practice and revolutionize your approach to healing.